Search results for "Neoplastic"

showing 10 items of 2901 documents

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a pha…

2008

Abstract Background This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer. Patients and methods Cetuximab was administered weekly: 400 mg/m2 initial dose, then 250 mg/m2 and FUFOX: oxaliplatin 50 mg/m2, FA 500 mg/m2 and 5-FU as a 24-h infusion at either 1500 or 2000 mg/m2 administered for 4 weeks followed by a 1-week rest (one cycle). Results Dose-limiting toxicity (grade 3 diarrhea) occurred in 3 of 14 assessable patien…

Malemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.drug_classLeucovorinCetuximabAntibodies Monoclonal HumanizedGastroenterologyAntimetaboliteDisease-Free SurvivalFolinic acidPharmacokineticsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCetuximabDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseOxaliplatinSurgeryIrinotecanErbB ReceptorsOxaliplatinOncologyFluorouracilPatient ComplianceFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Chemotherapy of metastatic colon cancer in France: A population-based study

2021

International audience; Aims: to describe, using data from a cancer registry in a well-defined French population, the therapeutic strategies and survival of patients with metastatic colon cancer (mCC).Methods: all patients with synchronous mCC diagnosed within the 2005-2014 period recorded in the digestive cancers registry of Burgundy were included.Results: 1286 mCC patients were included (57% male), of which 34.5% did not receive any antitumor treatment. Both, advanced age (≥75 years) and the Charlson comorbidity score ≥2 were significantly associated with the absence of antitumor treatment. Among the patients treated with chemotherapy, 59 and 33% received at least two and three lines, res…

Malemedicine.medical_specialtyOrganoplatinum Compounds[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinAdenocarcinomaPopulation-basedTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyIn patientRegistrieseducationAgedRetrospective StudiesMetastatic colon cancerChemotherapyeducation.field_of_studyHepatologyMetastatic colorectal cancerbusiness.industryPalliative CareComorbidity scoreAge FactorsGastroenterologyMiddle Aged3. Good healthCancer registry[SDV] Life Sciences [q-bio]Population based study030220 oncology & carcinogenesisColonic NeoplasmsCamptothecinFemale030211 gastroenterology & hepatologyFluorouracilFrancebusiness
researchProduct

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from th…

2013

International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for…

Malemedicine.medical_specialtyPalliative careSurvivalPopulation[SDV.CAN]Life Sciences [q-bio]/Cancerlymphoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/Cancerimmune system diseasesInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHypoalbuminemiaeducationSerum Albumin030304 developmental biologyCause of deathRetrospective StudiesAged 80 and over0303 health scienceseducation.field_of_studypalliative carebusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHematologymedicine.diseasePrognosisComorbidity3. Good healthLymphomaSurgeryaged 80 and overcomorbidityOncology030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?

2015

Objective Knowledge about determinants of participation in lifestyle interventions in cancer patients undergoing chemotherapy, particularly with palliative intent, remains poor. The objective of the present study was to identify determinants of participating in a 12 month individualized, comprehensive lifestyle intervention, focusing on diet, physical activity, mental stress and smoking cessation, in cancer patients receiving chemotherapy with curative or palliative intent. The secondary objective was to identify participation determinants 4 months into the study. Methods Newly diagnosed cancer patients starting chemotherapy at the cancer center in Kristiansand/Norway (during a 16 month inc…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentlcsh:MedicineAntineoplastic AgentsBreast NeoplasmsBreast cancerInternal medicinemedicineHumansPrecision Medicinelcsh:ScienceLife StyleSocioeconomic statusAgedChemotherapyMultidisciplinarybusiness.industryPalliative Carelcsh:RProstatic NeoplasmsCancerMiddle Agedmedicine.diseaseCombined Modality TherapyPhysical therapySmoking cessationMarital statusFemaleSmoking Cessationlcsh:QColorectal NeoplasmsbusinessBody mass indexResearch ArticlePLOS ONE
researchProduct

Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-α in pancreatic and periampullary cancer: Results of a feasibility study

2008

Abstract Background Recent studies give rise to the hypothesis, that adjuvant chemoradioimmunotherapy with 5-fluorouracil (5-FU), cisplatin and interferon-α (IFN-α) might be a possible new treatment of pancreatic cancer in resected patients. We report the up-to-now experience at our institution. Patients and methods Eleven patients with histological diagnosis of localized carcinoma of the pancreas ( n  = 7) or periampullary ( n  = 4) were prospectively analyzed. Four patients were deemed unresectable because of local invasion of adjacent organs (neoadjuvant setting) and seven patients underwent curative resection (adjuvant setting). Eight patients were classified as T3 carcinomas and three …

Malemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentAntineoplastic AgentsRisk AssessmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicinePeriampullary cancerHumansNeoplasm InvasivenessRadiology Nuclear Medicine and imagingSurvival rateNeoplasm Staging030304 developmental biology0303 health sciencesbusiness.industryPatient SelectionRadiotherapy Dosagemedicine.diseaseCombined Modality Therapypeople.cause_of_deathRecombinant Proteins3. Good healthSurgeryPancreatic NeoplasmsSurvival RateRadiation therapyOncology030220 oncology & carcinogenesisConcomitantInterferon Type IFeasibility StudiesFemaleFluorouracilImmunotherapyCisplatinbusinesspeopleChemoradiotherapyProgressive diseaseCancer/Radiothérapie
researchProduct

Clinical significance of abdominal lymphadenopathy in chronic liver disease

2002

Abstract The possibility of assessing the relationship of ultrasound (US)-detected abdominal lymphadenopathy with etiology, biochemical findings, and histologic data in patients with chronic liver disease was evaluated. US examination of the upper abdomen was performed in 321 consecutive patients with various chronic liver disorders and 56 control patients. The prevalence of lymphadenopathy in chronic liver disease was 38%. This prevalence varied according to etiology of liver disease, from 50% in chronic hepatitis C virus (HCV) to less than 10% in alcoholicc cirrhosis and hepatitis B-virus (HBV)-related chronic liver disease. Patients with lymphadenopathy showed significantly higher serum …

Malemedicine.medical_specialtyPathologyCirrhosisAcoustics and UltrasonicsHepatitis C virusBiophysicsAntineoplastic Agentsmedicine.disease_causeChronic liver diseaseGastroenterologyLiver diseaseInternal medicineAbdomenmedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesLymphatic DiseasesUltrasonographyHepatitis B virusHepatitisAnalysis of VarianceRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryLiver DiseasesInterferon-alphaMiddle Agedmedicine.diseasemedicine.anatomical_structureLiverLiver biopsyChronic DiseaseAbdomenFemaleLymph NodesbusinessUltrasound in Medicine & Biology
researchProduct

[Clinical practice and adherence to the diagnosis and treatment of NMIBC guidelines: a report of a recognition based clinical cases study]

2014

For non-muscle invasive bladder cancer, a disease with a considerable epidemiological and socio-economic impact, the introduction of the Guidelines has always evoked as a tool for the resolution of long-standing disputes in terms of diagnosis and therapy. Check the degree of routine clinical practice adherence to the Recommendations is for this disease, more than for other uro-oncology pathology, an urgent need felt by the urological community. To assess the level of Guidelines adherence's, and study issues related to the paths of diagnosis and treatment of non-muscle invasive bladder cancer, and identifying the processes actually implemented in daily clinical practice, a series of case st…

Malemedicine.medical_specialtyPathologyMEDLINEAntineoplastic AgentsDiseaseEpidemiologymedicineHumansRoutine clinical practiceIntensive care medicineNeoplasm StagingBladder cancerbusiness.industryCarcinomaGeneral MedicineEvidence-based medicineMiddle Agedmedicine.diseaseClinical PracticeAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsChemotherapy AdjuvantPractice Guidelines as TopicBCG VaccineGuideline AdherencebusinessStrengths and weaknesses
researchProduct

Survival of Mycosis Fungoides in Patients in the Southeast of England

2004

<i>Background:</i> Mycosis fungoides (MF) is the most common skin lymphoma. The aetiology of MF remains unknown, and no therapy has to date significantly altered patient survival. <i>Objective:</i> The present study examines trends in survival of MF patients in a well-defined population-based disease group, namely patients registered over a 40-year period at the Thames Cancer Registry, Southeast England. <i>Methods:</i> The Thames Cancer Registry is a population-based registry, covering a population of approximately 14 million people. Data were taken from the Surveillance, Epidemiology and End Results cancer registry programme and the National Centre for …

Malemedicine.medical_specialtyPathologySkin NeoplasmsAntineoplastic Agents HormonalDermatologyCohort StudiesMycosis FungoidesSex FactorsResidence CharacteristicsEpidemiologymedicineHumansSezary SyndromeIn patientRegistriesSurvival rateAgedProportional Hazards ModelsMycosis fungoidesbusiness.industryProportional hazards modelAge FactorsMiddle AgedPrognosismedicine.diseaseDermatologyPeripheral T-cell lymphomaLymphomaSurvival RateEnglandPopulation SurveillanceEtiologyFemalebusinessFollow-Up StudiesSEER Program
researchProduct

Comparison of enzyme phenotypes in human bladder tumours and experimentally induced hyperplastic and neoplastic lesions of the rat urinary bladder. A…

1988

The expression of a number of enzymes involved in drug metabolism, membrane function etc. was compared in hyperplastic and neoplastic lesions of the rat bladder and in human bladder tumours. Transitional cell carcinomas (TCC) in both rat and Man were characterized by decreased alkaline phosphatase (ALP) and increased gamma-glutamyl transpeptidase (GGT), beta-glucuronidase (beta-G1), succinate dehydrogenase (SD) and glucose-6-phosphate dehydrogenase (G6PD) activities. In addition, binding for antibodies specific for different cytochrome P-450 species (UT50, PB3a, MC1, MC2) and microsomal epoxide hydrolase (mEHb) was elevated in both murine and human tumours. Comparison of the enzyme phenotyp…

Malemedicine.medical_specialtyPathologyUrinary BladderGlucosephosphate DehydrogenaseInternal medicinemedicineAnimalsHumansNeoplastic transformationEnzyme inducerGlucuronidaseCarcinoma Transitional CellUrinary bladderHyperplasiabiologyHistocytochemistrySuccinate dehydrogenasegamma-GlutamyltransferaseHyperplasiamedicine.diseaseAlkaline PhosphataseImmunohistochemistryRats Inbred F344RatsSuccinate DehydrogenaseEndocrinologymedicine.anatomical_structurePhenotypeUrinary Bladder NeoplasmsMicrosomal epoxide hydrolasebiology.proteinImmunohistochemistryDrug metabolismVirchows Archiv. B, Cell pathology including molecular pathology
researchProduct

Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically …

2009

OBJECTIVE To evaluate the expression of urokinase-plasminogen-activator receptor (uPA-R) in disseminated tumour cells (DTC) in bone marrow (BM) and peripheral blood (PB) of patients with clinically localized prostate cancer before radical prostatectomy (RP), and to assess the associations with pathological variables and prognosis. PATIENTS AND METHODS In all, 52 patients (47 with clinically localized cancer and five with benign prostatic hyperplasia, BPH, as controls) were prospectively enrolled. BM and PB samples were drawn before surgery. DTC were enriched using a commercial system, cytokeratin (CK) 8/18 was used to detect DTC, and uPA-R expression was detected by dual-immunostaining of t…

Malemedicine.medical_specialtyPathologyUrologyReceptor expressionmedicine.medical_treatmentGastroenterologyReceptors Urokinase Plasminogen ActivatorCytokeratinProstate cancerBone MarrowInternal medicinemedicineBiomarkers TumorHumansAgedProstatectomybusiness.industryProstatectomyCancerProstatic NeoplasmsHyperplasiaMiddle AgedProstate-Specific Antigenmedicine.diseaseNeoplastic Cells CirculatingPrognosisImmunohistochemistryUrokinase receptormedicine.anatomical_structureLymphatic MetastasisBone marrowNeoplasm Recurrence LocalbusinessEpidemiologic MethodsBJU international
researchProduct